Research

EAN Scientific Panel Neuro-oncology invites you to take part in their survey:

In this paper, just published in the New England Journal of Medicine, the authors report neuropathological findings from autopsies of 18 consecutive patients with SARS-CoV-2 infection who died in a single teaching hospital between April 14 and April 29, 2020.

This retrospective multicentre study aimed to assess the number of patients with acute ischaemic cerebrovascular events seeking inpatient medical emergency care since the implementation of social distancing measures during the COVID-19 pandemic.

In this paper recently published in Neurology, the authors aimed to determine whether neurological manifestations are common in hospitalised COVID-19 patients and to describe their main characteristics.

In this study, recently published in Neurology Neuroimmunology & Neuroinflammation, the authors conducted a survey on the risk of COVID-19 in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD).

In this paper, the authors report a case of Guillain-Barré syndrome (GBS) with onset 2 weeks after SARS-CoV-2 infection and highly elevated serum antibodies against SARS-CoV-2, supporting an association between SARS-CoV-2 disease and GBS.

In this prospective observational cohort study with rapid data gathering and near real-time analysis, the authors characterised the clinical features of patients admitted to hospital with Covid-19 in the United Kingdom during the growth phase of the first wave of the outbreak. Patients were enrolled in the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organisation (WHO) Clinical Characterisation Protocol UK (CCP-UK) study, and risk factors associated with mortality in hospital were explored.

Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In the present COVID-19 pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurological patients.

In this paper, the authors systematically analysed lung tissue samples from 38 patients who died from COVID-19 in two hospitals in northern Italy between Feb 29 and March 24 2020.

In this paper, just published in Lancet, the authors performed a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine in Wuhan, China.

In this paper, the authors investigated the effects of physical distance, face masks, and eye protection on virus transmission in healthcare and non-healthcare settings.

From the Spanish Society of Neurology, it is our pleasure to share with our European colleagues the Handbook on COVID-19 management for Neurologists.

On June 3, we published in the Breaking News section of this site the article entitled “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” previously published in Lancet. On June 13, the article was retracted by three of the four authors.

In this case series, the authors systematically assessed the presence of deep vein thrombosis among patients with severe COVID-19 in an intensive care unit (ICU) in France. They prospectively performed a venous ultrasonogram of the legs in all patients on admission to ICU and repeated the test after 48 hours if the first examination was normal. All patients received standard anticoagulant prophylaxis at hospital admission.

In this paper, recently published in Lancet, the authors report the findings of autopsies of six patients (four men and two women, aged 58–82 years) who died from COVID-19 in April 2020 in Munich, Germany. The period from onset of symptoms to admission ranged from 2–10 days.